Literature DB >> 25031145

Intravenous immunoglobulin in children with acute myocarditis and/or early dilated cardiomyopathy.

Amarendra N Prasad1, Sanjay Chaudhary.   

Abstract

We retrospectively studied medical records of all children with acute myocarditis and/or early DCM admitted to the Pediatric Critical Care Unit of our hospital between January 2010 and December 2012 were reviewed. 28 patients were included in the study, of which 12 were treated with IVIG (1 g/kg per day) for two days. The patients who received IVIG therapy had a higher left ventricular ejection fraction and a reduced left ventricular end diastolic diameter six months after treatment, as compared to children who had not received IVIG (P<0.001 and P=0.002, respectively).

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25031145     DOI: 10.1007/s13312-014-0456-2

Source DB:  PubMed          Journal:  Indian Pediatr        ISSN: 0019-6061            Impact factor:   1.411


  3 in total

1.  In-hospital and post-discharge outcomes of pediatric acute myocarditis underwent after high-dose steroid or intravenous immunoglobulin therapy.

Authors:  Ming-Shyan Lin; Yu-Hsiang Tseng; Mei-Yen Chen; Chang-Min Chung; Ming-Horng Tsai; Po-Chang Wang; Jung-Jung Chang; Tien-Hsing Chen; Yu-Sheng Lin
Journal:  BMC Cardiovasc Disord       Date:  2019-01-09       Impact factor: 2.298

2.  Role of intravenous immunoglobulin therapy in the survival rate of pediatric patients with acute myocarditis: A systematic review and meta-analysis.

Authors:  Chun-Yu Yen; Miao-Chiu Hung; Ying-Chi Wong; Chia-Yuan Chang; Chou-Cheng Lai; Keh-Gong Wu
Journal:  Sci Rep       Date:  2019-07-18       Impact factor: 4.379

3.  Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double-blind, randomized, placebo-controlled clinical trial.

Authors:  Mark R Hazebroek; Michiel T H M Henkens; Anne G Raafs; Job A J Verdonschot; Jort J Merken; Robert M Dennert; Casper Eurlings; Myrurgia A Abdul Hamid; Petra F G Wolffs; Bjorn Winkens; Hans-Peter Brunner-La Rocca; Christian Knackstedt; Pieter van Paassen; Vanessa P M van Empel; Stephane R B Heymans
Journal:  Eur J Heart Fail       Date:  2021-01-07       Impact factor: 15.534

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.